On April 24, 2012, Lipid Sciences Inc. went out of business on completion of liquidation under Chapter 7. Lipid Sciences, Inc. was a development-stage biotechnology company engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease, human immunodeficiency virus (HIV) and other viral infections, in which lipids or fat components play a key role. The Company's technologies were based on a process that selectively and rapidly removes lipids, such as cholesterol from lipoproteins or viruses circulating in blood plasma without disrupting protein function. This process of lipid removal, known as delipidation, potentially improves the condition while enhancing the body's natural ability to heal itself. Lipid Sciences was focused on applications for delipidation in two main areas: cardiovascular disease, using its HDL Therapy platform, and viral infections, using its Viral Immunotherapy platform.
